Clinical Trials Arena on MSN8h
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...
pharmaphorum3d
Neurocrine achieves a first with tardive dyskinesia drug Ingrezza
Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...
Hosted on MSN1mon
Neurocrine stock target cut to $185 at H.C. Wainwright
unlike its competitor Austedo. Additionally, Ingrezza is not contraindicated in patients with hepatic impairments or those taking certain medications, which could further support its adoption.